Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies,including investigational treatments for anaphylaxis and potentially, alopecia areata.
Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We also manufacture and package a wide range of pharmaceutical and wellness products, including oral films,creams, and lotions, for our contract licensees and customers.
“Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.”
Dan Barber
President and Chief Executive Officer
Our leadership
Our experienced Leadership Team and active Board of Directors bring deep industry expertise and a shared commitment to scientific innovation, responsible growth, and improving patients’ lives.
MEET OUR
Executive Leadership Team
MEET OUR
Board of Directors
MEET OUR
Scientific Advisory Board
Our history
Founded in 2005, Aquestive has spent two decades building a category-defining drug delivery platform with PharmFilm, earning the trust of patients, doctors, and shareholders through consistent innovation and execution.
2005
We are founded as MonoSol Rx
2006
We open our first manufacturing and development facility in Indiana
2010
We receive our first two FDA approvals
for Zuplenz (ondansetron) oral soluble film and Suboxone (buprenorphine and naloxone) sublingual film
2013
We begin research and development
for central nervous system (CNS) medicines
2016
We file Investigational New Drug Applications
for diazepam, clobazam, and riluzole
2017
We officially become Aquestive Therapeutics
2018
We become a publicly traded company on the NASDAQ: AQST
2019
We receive additional FDA-approvals
for Sympazam (clobazam) oral film and Exservan (riluzole) oral film
2020
LIBERVANT® (diazepam) buccal film
New Drug Application accepted by the FDA
2025
ANAPHYLM™ (dibutepinephrine) sublingual film
New Drug Application accepted by the FDA
2005
We are founded as MonoSol Rx
2006
We open our first manufacturing and development facility in Indiana
2010
We receive our first two FDA approvals
for Zuplenz (ondansetron) oral soluble film and Suboxone (buprenorphine and naloxone) sublingual film
2013
We begin research and development
for central nervous system (CNS) medicines
2016
We file Investigational New Drug Applications
for diazepam, clobazam, and riluzole
2017
We officially become Aquestive Therapeutics
2018
We become a publicly traded company on the NASDAQ: AQST
2019
We receive additional FDA-approvals
for Sympazam (clobazam) oral film and Exservan (riluzole) oral film
2020
LIBERVANT® (diazepam) buccal film
New Drug Application accepted by the FDA
2025
ANAPHYLM™ (dibutepinephrine) sublingual film
New Drug Application accepted by the FDA
Our responsibilities
Aquestive is committed to ethical conduct, environmental stewardship, and transparent corporate governance. We maintain high standards across compliance, marketing, and sustainability.
Our compliance program incorporates the elements of an effective compliance program in accordance with the “Compliance Program Guidance” for Pharmaceutical Manufacturers” (“OIG Guidance”) developed by the United States Department of Health and Human Services, Office of Inspector General (“OIG”) and our programs follow the PhRMA "Code Of Conduct When Interacting With Health Care Professionals."
